These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 30060231)
1. Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies. Ilinykh PA; Graber J; Kuzmina NA; Huang K; Ksiazek TG; Crowe JE; Bukreyev A J Infect Dis; 2018 Nov; 218(suppl_5):S418-S422. PubMed ID: 30060231 [TBL] [Abstract][Full Text] [Related]
2. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276 [TBL] [Abstract][Full Text] [Related]
3. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854 [TBL] [Abstract][Full Text] [Related]
4. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655 [TBL] [Abstract][Full Text] [Related]
5. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917 [TBL] [Abstract][Full Text] [Related]
6. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop. Mire CE; Geisbert TW Trends Mol Med; 2017 Aug; 23(8):669-671. PubMed ID: 28697885 [TBL] [Abstract][Full Text] [Related]
7. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model. Duehr J; Wohlbold TJ; Oestereich L; Chromikova V; Amanat F; Rajendran M; Gomez-Medina S; Mena I; tenOever BR; García-Sastre A; Basler CF; Munoz-Fontela C; Krammer F J Virol; 2017 Aug; 91(16):. PubMed ID: 28592526 [TBL] [Abstract][Full Text] [Related]
8. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263 [TBL] [Abstract][Full Text] [Related]
9. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Bornholdt ZA; Herbert AS; Mire CE; He S; Cross RW; Wec AZ; Abelson DM; Geisbert JB; James RM; Rahim MN; Zhu W; Borisevich V; Banadyga L; Gunn BM; Agans KN; Wirchnianski AS; Goodwin E; Tierney K; Shestowsky WS; Bohorov O; Bohorova N; Velasco J; Ailor E; Kim D; Pauly MH; Whaley KJ; Alter G; Walker LM; Chandran K; Zeitlin L; Qiu X; Geisbert TW; Dye JM Cell Host Microbe; 2019 Jan; 25(1):49-58.e5. PubMed ID: 30629918 [TBL] [Abstract][Full Text] [Related]
10. Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection. Shcheblyakov D; Esmagambetov I; Simakin P; Kostina L; Kozlov A; Tsibezov V; Grebennikova T; Chifanov D; Rumyantseva I; Boyarskaya N; Sizikova T; Shagarova N; Andrus А; Shatohina I; Syromyatnikova S; Kovalchuk A; Pantyukhov V; Borisevich S; Zubkova O; Tukhvatulin A; Logunov D; Naroditsky B; Gintsburg A Antiviral Res; 2019 Dec; 172():104617. PubMed ID: 31593751 [TBL] [Abstract][Full Text] [Related]
11. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755 [TBL] [Abstract][Full Text] [Related]
12. Discovery of an antibody for pan-ebolavirus therapy. Furuyama W; Marzi A; Nanbo A; Haddock E; Maruyama J; Miyamoto H; Igarashi M; Yoshida R; Noyori O; Feldmann H; Takada A Sci Rep; 2016 Feb; 6():20514. PubMed ID: 26861827 [TBL] [Abstract][Full Text] [Related]
13. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO mBio; 2018 Sep; 9(5):. PubMed ID: 30206174 [TBL] [Abstract][Full Text] [Related]